Exagen Inc reports results for the quarter ended in December - Earnings Summary

Exagen

20/03/2023 21:01

* Exagen Inc  XGN.OQ  reported a quarterly adjusted loss
of 83
cents​​ per share for the quarter ended in December. The mean
expectation of six analysts for the quarter was for a loss of 78
cents per share.
    * Revenue rose 1.2% to $12.84 million from a year ago;
analysts
expected $8.66 million. 
    * Exagen Inc's reported EPS for the quarter was a loss of 83
cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Exagen Inc shares had fallen by 5.8% this quarter.
    * The company reported a quarterly loss of $14.35 million.
    * Wall Street's median 12-month price target for Exagen Inc
is
$6.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 20 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.78          -0.83          Missed
 Sep. 30 2022      -0.73          -0.47          Beat
 Jun. 30 2022      -0.57          -0.78          Missed
 Mar. 31 2022      -0.61          -0.60          Beat